LQDAHealthcare · Drug Manufacturers - Specialty & GenericThe 8 Wall Street analysts covering Liquidia Corp. hold a median 12-month price target of $57 — +24.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 76 of 100 as at 27 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Liquidia Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (100): The business earns solid, repeatable profits on what it owns.
Issuance (18): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on LQDA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +24.3% from it.
Of the 20 most recent actions, 5 moved their price target up and 5 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 15 Oct 2026 | HC Wainwright & Co. | Maintains | Buy | $58 → $65 |
| 14 Oct 2026 | BTIG | Upgrade | Buy | $70 |
| 14 Oct 2026 | LifeSci Capital | Upgrade | Outperform | $59 |
| 14 Oct 2026 | Needham | Maintains | Buy | $72 → $58 |
| 14 Oct 2026 | Wells Fargo | Maintains | Equal-Weight | $30 → $33 |
| 2 Oct 2026 | HC Wainwright & Co. | Maintains | Buy | $130 → $58 |
| 2 Oct 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 2 Oct 2026 | Wells Fargo | Downgrade | Equal-Weight | — |
| 2 Oct 2026 | Wells Fargo | Downgrade | Equal-Weight | $108 → $30 |
| 1 Oct 2026 | BTIG | Downgrade | Neutral | — |
| 1 Oct 2026 | BTIG | Downgrade | Neutral | — |
| 1 Oct 2026 | Needham | Maintains | Buy | — |
| 1 Oct 2026 | Needham | Maintains | Buy | $110 → $72 |
| 1 Oct 2026 | Raymond James | Downgrade | Outperform | — |
| 1 Oct 2026 | Raymond James | Downgrade | Outperform | $106 → $53 |
| 13 Aug 2026 | B of A Securities | Maintains | Neutral | $79 → $92 |
| 13 Aug 2026 | B of A Securities | Maintains | Neutral | — |
| 13 Aug 2026 | Wells Fargo | Maintains | Overweight | $62 → $108 |
| 13 Aug 2026 | Wells Fargo | Maintains | Overweight | — |
| 12 Aug 2026 | BTIG | Maintains | Buy | $109 → $111 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
LQDA appears in the Radar on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 27 Oct 2026, Liquidia Corp. returned +99.6% against +13.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 24% of US stocks
Cheaper than 15% of US stocks
Cheaper than 5% of US stocks
Cheaper than 12% of US stocks
Higher than 99% of US stocks
Higher than 98% of US stocks
Higher than 97% of US stocks
Higher than 96% of US stocks
Higher than 89% of US stocks
Higher than 97% of US stocks
Higher than 99% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Liquidia Corp. has a market value of $3.9B and an enterprise value of $3.8B.
Revenue in the twelve months to 30 June 2026: $450.9M. The latest quarter grew 1842.7% year on year.
Net income over the same four quarters: $138.6M, a 30.7% net margin.
Diluted earnings per share, trailing twelve months: $1.37.
Free cash flow in the twelve months to 30 June 2026: $147.7M.
Trailing P/E: 31.5×; forward P/E: 20.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Liquidia Corp. employs 216 people — $2.1M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Liquidia Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research reports that Liquidia does not have the two key ingredients associated with a likely earnings beat in its upcoming report. The article highlights expectations for the report.
Why it matters — LQDA watchers may note the article’s assessment of the factors tied to a potential earnings beat ahead of the upcoming report.
Liquidia settled six legal disputes with United Therapeutics, securing Yutrepia access for PAH patients. The settlement includes $380.7 million in payments and a narrower drug label.
Why it matters — The resolution secures access for PAH patients while imposing substantial payments and limiting Yutrepia’s label.
Liquidia shares rose 25% to $33.47 after the company settled all six pending lawsuits with United Therapeutics, ending years of patent and antitrust disputes.
Why it matters — The agreement removes a major source of legal uncertainty surrounding YUTREPIA, Liquidia’s inhaled treprostinil treatment for pulmonary arterial hypertension.
Liquidia and United Therapeutics ended their patent dispute in a settlement. The excerpt says the settlement followed a ruling that erased nearly half of Liquidia’s stock value in one day and cost the company almost all of its cash on hand.
Why it matters — The resolution and its reported cost are relevant to LQDA watchers assessing the company’s patent dispute and financial position.
Liquidia shares surged 37% after the company reached a $380.7 million settlement with United Therapeutics, resolving patent disputes involving its lung disease drug.
Why it matters — The settlement resolves a patent dispute relevant to Liquidia and its lung disease drug.
The 8 Wall Street analysts covering Liquidia Corp. have a median 12-month price target of $57, with estimates ranging from $33 to $70. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 8 analysts covering Liquidia Corp., 6 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Liquidia Corp. 76 out of 100 across roughly 4,600 US stocks as at 27 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 27 Oct 2026, Liquidia Corp. ranks 76 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (100 of 100).
No one can know that. What the data says: the median 12-month target from 8 analysts implies +24.3% from the last close, and Ticker Nerd's factor model ranks Liquidia Corp. 76 out of 100 as at 27 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Liquidia Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LQDA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $33 to $70 over the next 12 months.
Liquidia Corp. returned +99.6% over the 12 months to 27 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Liquidia Corporation is a biopharmaceutical company focused on developing, manufacturing, and commercializing therapies for rare cardiopulmonary diseases. The company’s current portfolio centers on treatments for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, supported by its proprietary PRINT particle-engineering platform, which is designed to create precise drug particles for inhaled and other advanced delivery formats.
The most recent item we track (Zacks Investment Research, 26 Oct 2026): "Liquidia Corporation (LQDA) Earnings Expected to Grow: Should You Buy?". Zacks Investment Research reports that Liquidia does not have the two key ingredients associated with a likely earnings beat in its upcoming report. The article highlights expectations for the report.
Liquidia Corporation is a biopharmaceutical company focused on developing, manufacturing, and commercializing therapies for rare cardiopulmonary diseases. The company’s current portfolio centers on treatments for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, supported by its proprietary PRINT particle-engineering platform, which is designed to create precise drug particles for inhaled and other advanced delivery formats. Liquidia’s work spans product development, manufacturing, and commercialization, giving it a role across the full lifecycle of specialty respiratory medicines. Its marketed and investigational programs are aimed at patients with challenging respiratory and vascular conditions, positioning the company within the rare-disease and specialty pharmaceutical markets. Liquidia Corporation is headquartered in Morrisville, North Carolina.
CEO Dr. Roger A. Jeffs Ph.D. · 216 employees · United States · https://www.liquidia.com
